Koen Totté

Koen Totté

Auto-generated profile, based on publicly available information

Koen Totté

Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2026 in Journal of Infection
Verified
Journal Article
Open access
LBLucille van Beek
Lucille van Beek
SCSuzanne E.T. Comans
Suzanne E.T. Comans
KTKoen Totté
Koen Totté
JFJaneri Fröberg
Janeri Fröberg
CJChrista E. van der Gaast-De Jongh
Christa E. van der Gaast-De Jongh
DDDimitri A. Diavatopoulos
Dimitri A. Diavatopoulos
Colonisation of the upper airways by Streptococcus pneumoniae is a prerequisite for disease development and shapes immune responses that vary between geographical settings. This first controlled human pneumococcal infection study in the Netherlands assessed colonisation, antibody responses, respiratory symptoms, and concurrent viral infections. Twenty healthy adults (19-47 years) were enrolled between May 2022 and February 2023 and inoculated intranasally with 160,000 colony forming units of S. pneumoniae serotype 6B (strain BHN418). Participants were monitored for 28 days to assess colonisation, respiratory viral infection and safety. Serum and nasal lining fluid were collected to measure IgA, IgM and IgG responses to serotype 6B polysaccharide (6B) and whole pneumococci. Eight of 20 participants (40%) became colonised. Colonised participants showed significant rises in serum and mucosal IgG and IgA to 6B, but not to pneumococci. Fifteen participants tested positive for at least one respiratory virus. Symptoms were generally mild but occurred more often in those with concurrent pneumococcal colonisation and viral infection. Colonisation rates were comparable to studies in other populations. Colonisation induced systemic and mucosal antibody responses, while viral co-infection increased symptom burden. This controlled infection study demonstrates feasibility and safety, and establishes a platform for vaccine evaluation and pneumococcal-viral interaction studies.

10 September 2026 in Digestive Diseases and Sciences
Verified
Journal Article
Open access
PDF file
EGE. Godecharle
E. Godecharle
KTK. Totté
K. Totté
WBWillem Brink
Willem Brink
ZMZlatan Mujagic
Zlatan Mujagic
JZJ. Zhang
J. Zhang
MPMarieke J. Pierik
Marieke J. Pierik
Purpose Wearable-derived digital biomarkers represent a new frontier in remote management of inflammatory bowel disease (IBD). They may enable continuous disease surveillance and early flare detection while reducing reliance on questionnaire-based remote monitoring. However, successful implementation into clinical practice critically depends on patient acceptance and perceived relevance. To guide patient-centered digital health strategies, we aimed to investigate patient perspectives on digital biomarkers for (early) flare detection. Methods A nationwide cross-sectional survey-based study was conducted among patients with IBD (≥ 16 years) in the Netherlands. A study-specific questionnaire was distributed through the Dutch patient organization Crohn & Colitis NL to assess acceptance, preferences, and perspectives on the use of wearable technology for flare detection. Results 1,080 participants were included: 72.5% women, 53.4% aged >50 years, and 28.7% current wearable users. Overall, 88% considered remote monitoring for flare detection potentially useful, and over 90% believed wearables could support this. Motivations for using wearables included flare detection, better understanding of symptoms, and health monitoring. User-friendliness, clear alerts, and time efficiency were key device preferences, and smartwatches were the preferred wearable device. Shorter disease duration (p<0.001), more frequent flares (p=0.029), younger age (p=0.016), and current wearable use (p<0.001) were identified as predictors for willingness to use wearables. Conclusion Patients with IBD value wearables for flare detection and disease-monitoring. Most participants expressed willingness to use digital biomarkers and believed that wearables could support routine care. Incorporating patient preferences into digital biomarker development will likely improve patient acceptance and adherence to remote monitoring.

25 May 2026 in JCC Plus
Verified
Journal Article
Open access
KTKoen Totté
Koen Totté
LVLoriane Verleye
Loriane Verleye
RWRachel West
Rachel West
ABAlexander Bodelier
Alexander Bodelier
WDWillemijn van Dop
Willemijn van Dop
T(The Ibdream And The Dutch Initiative On Crohn And Colitis (Icc)
The Ibdream And The Dutch Initiative On Crohn And Colitis (Icc)
Background: Clinical trials have demonstrated the long‐term efficacy of ustekinumab in the treatment of ulcerative colitis (UC). However, real‐world data on its long‐term effectiveness beyond 1 year of follow‐up remain limited. Methods: This multicenter cohort study evaluated the effectiveness of ustekinumab in adults with UC treated in routine clinical practice for up to 4 years. Data were obtained from two prospective Dutch registries: IBDREAM and the ICC registry. The primary outcome was corticosteroid‐free remission at year 3, with remission defined as a hierarchical, composite endpoint based on endoscopic, biochemical, and clinical parameters. Subgroup analysis was performed in patients with difficult‐to‐treat IBD, defined as prior failure of ≥ 2 advanced therapies with different mechanisms of action. Secondary outcomes included dose escalation and safety. Results: A total of 198 patients were included; median age was 49 years, 48% were women, median disease duration was 8 years, and 42.4% had difficult‐to‐treat IBD. At years 2, 3, and 4, 35.8% (49/137), 34.3% (34/99), and 26.6% (17/64) of patients were in corticosteroid‐free remission. Among patients in corticosteroid‐free remission at week 12 ( n = 83), 50.0% remained in remission at year 3. Corticosteroid‐free remission rates at year 3 in patients with difficult‐to‐treat IBD and other patients were 19.2% and 51.1%, respectively. One‐hundred‐seven adverse events were recorded in 64 patients, including six serious adverse events. Conclusion: These real‐world data confirm the effectiveness of ustekinumab in inducing and maintaining remission for up to 4 years in UC. The medication was particularly effective in patients with limited prior exposure to advanced therapies. Results support the established safety profile of ustekinumab.